Sorbara Marie, Cordelier Pierre, Bery Nicolas
Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, 31100 Toulouse, France.
Antibodies (Basel). 2022 Jul 12;11(3):47. doi: 10.3390/antib11030047.
Pancreatic cancer is an aggressive cancer with a dismal prognosis. This is due to the difficulty to detect the disease at an early and curable stage. In addition, only limited treatment options are available, and they are confronted by mechanisms of resistance. Monoclonal antibody (mAb) molecules are highly specific biologics that can be directly used as a blocking agent or modified to deliver a drug payload depending on the desired outcome. They are widely used to target extracellular proteins, but they can also be employed to inhibit intracellular proteins, such as oncoproteins. While mAbs are a class of therapeutics that have been successfully employed to treat many cancers, they have shown only limited efficacy in pancreatic cancer as a monotherapy so far. In this review, we will discuss the challenges, opportunities and hopes to use mAbs for pancreatic cancer treatment, diagnostics and imagery.
胰腺癌是一种侵袭性癌症，预后很差。这是因为在早期可治愈阶段很难检测到这种疾病。此外，可用的治疗选择有限，并且它们面临耐药机制。单克隆抗体（mAb）分子是高度特异性的生物制剂，可根据预期结果直接用作阻断剂或进行修饰以递送药物有效载荷。它们广泛用于靶向细胞外蛋白，但也可用于抑制细胞内蛋白，如癌蛋白。虽然单克隆抗体是一类已成功用于治疗许多癌症的疗法，但到目前为止，它们作为单一疗法在胰腺癌中仅显示出有限的疗效。在这篇综述中，我们将讨论使用单克隆抗体治疗、诊断和成像胰腺癌所面临的挑战、机遇和希望。
